Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) by 4.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 94,568 shares of the company’s stock after acquiring an additional 3,814 shares during the quarter. Russell Investments Group Ltd.’s holdings in Deciphera Pharmaceuticals were worth $1,550,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can acquired a new position in Deciphera Pharmaceuticals in the third quarter valued at $43,000. Lazard Asset Management LLC acquired a new position in shares of Deciphera Pharmaceuticals during the third quarter worth about $69,000. US Bancorp DE lifted its stake in shares of Deciphera Pharmaceuticals by 19.4% during the third quarter. US Bancorp DE now owns 4,840 shares of the company’s stock worth $90,000 after purchasing an additional 788 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of Deciphera Pharmaceuticals during the third quarter worth about $124,000. Finally, UBS Oconnor LLC acquired a new position in shares of Deciphera Pharmaceuticals during the third quarter worth about $185,000. Institutional investors and hedge funds own 72.66% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on DCPH shares. Cowen boosted their price objective on Deciphera Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 25th. Stifel Nicolaus dropped their target price on Deciphera Pharmaceuticals from $17.00 to $14.00 in a research report on Thursday, May 4th. SVB Leerink lifted their target price on Deciphera Pharmaceuticals from $28.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 7th. JMP Securities reaffirmed a “market outperform” rating and set a $23.00 target price on shares of Deciphera Pharmaceuticals in a research report on Wednesday, March 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Deciphera Pharmaceuticals in a research report on Wednesday, February 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.78.

Deciphera Pharmaceuticals Stock Up 1.2 %

Shares of DCPH stock opened at $14.49 on Wednesday. The business has a 50 day moving average of $14.67 and a two-hundred day moving average of $15.82. Deciphera Pharmaceuticals, Inc. has a 52 week low of $10.14 and a 52 week high of $22.76. The company has a market cap of $1.14 billion, a P/E ratio of -6.17 and a beta of 0.68.

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last issued its earnings results on Wednesday, May 3rd. The company reported ($0.60) EPS for the quarter, meeting analysts’ consensus estimates of ($0.60). Deciphera Pharmaceuticals had a negative return on equity of 46.56% and a negative net margin of 131.38%. The company had revenue of $33.45 million during the quarter, compared to the consensus estimate of $35.50 million. During the same period in the previous year, the firm posted ($0.80) earnings per share. Deciphera Pharmaceuticals’s quarterly revenue was up 14.4% compared to the same quarter last year. Analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.47 EPS for the current fiscal year.

Insider Buying and Selling at Deciphera Pharmaceuticals

In other Deciphera Pharmaceuticals news, Director Dennis Leo Walsh acquired 11,000 shares of Deciphera Pharmaceuticals stock in a transaction dated Wednesday, May 10th. The stock was acquired at an average cost of $13.86 per share, for a total transaction of $152,460.00. Following the completion of the transaction, the director now owns 11,000 shares in the company, valued at approximately $152,460. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Deciphera Pharmaceuticals news, Director Dennis Leo Walsh acquired 11,000 shares of Deciphera Pharmaceuticals stock in a transaction dated Wednesday, May 10th. The stock was acquired at an average cost of $13.86 per share, for a total transaction of $152,460.00. Following the completion of the transaction, the director now owns 11,000 shares in the company, valued at approximately $152,460. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Steven L. Hoerter sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 21st. The stock was sold at an average price of $15.57, for a total value of $116,775.00. The disclosure for this sale can be found here. 4.43% of the stock is currently owned by insiders.

Deciphera Pharmaceuticals Company Profile

(Get Rating)

Deciphera Pharmaceuticals, Inc is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors.